{"id":1950,"date":"2013-09-06T22:44:24","date_gmt":"2013-09-06T22:44:24","guid":{"rendered":"http:\/\/www3.law.harvard.edu\/orgs\/lids\/?post_type=tribe_events&p=1950"},"modified":"2013-09-06T23:02:51","modified_gmt":"2013-09-06T23:02:51","slug":"lids-co-hosting-event-compulsory-license-and-access-to-medicines-the-indian-experience-to-date","status":"publish","type":"tribe_events","link":"https:\/\/orgs.law.harvard.edu\/lids\/event\/lids-co-hosting-event-compulsory-license-and-access-to-medicines-the-indian-experience-to-date\/","title":{"rendered":"Compulsory License and Access to Medicines: The Indian Experience To Date"},"content":{"rendered":"

Event Date:\u00a0\u00a0Monday, Sept. 16, 2013\u00a0<\/strong><\/p>\n

Event Time:\u00a0\u00a012:00-1:00 p.m.<\/strong><\/p>\n

Event Location:\u00a0 Wasserstein Hall Room B015,\u00a0 Harvard Law School<\/strong><\/p>\n


\n\"wto\"<\/a><\/strong><\/p>\n

Description:<\/strong><\/p>\n

Mr. V. Lakshmikumaran is the founder and managing partner of Lakshmikumaran & Sridharan (L&S).\u00a0 L&S is one of India\u2019s elite law firms, serving\u00a0several Fortune 500 and top Indian companies in international trade, tax, intellectual property, and corporate matters.\u00a0 \u00a0Chambers Asia Pacific recently declared\u00a0several L&S\u2019s practices to be in the top-tier and \u00a0exclaimed that Mr. Lakshmikumaran \u201cpossesses a virtual monopoly when it comes to indirect tax litigation\u201d in India. \u00a0Besides corporate and tax matters, L&S handles high-profile intellectual property (IP) cases and has been retained by the Indian government to argue several cases on its behalf before the World Trade Organization (WTO).<\/p>\n

Mr. Lakshmikumaran\u2019s talk will focus on India\u2019s compulsory licensing regime, which can be used to mandate that an IP holder license its IP right to another company or individual for a fee.\u00a0 In 2012, India\u2019s government first exercised its power to issue a compulsory license, allowing a generic pharmaceutical company, Natco, to manufacture a version of the cancer-fighting drug, Nexavar, developed by Bayer, after finding, among others, the branded drug to be cost-prohibitive for India.\u00a0 This action is being closely watched worldwide because of the important role played by Indian companies in supplying affordable generic versions of medicines globally.\u00a0 In March 2013, the Indian Patent Appeals Body rejected an appeal from Bayer; the case is now before the High Court of Bombay. \u00a0If upheld, the development of this regime may be a game changer for global health, opening the way for other Indian generic pharmaceutical companies to seek compulsory licenses to manufacture cheaper version of essential drugs. \u00a0In fact, further applications have already been filed against Bristol-Meyers Squibb and Roche for other cancer-fighting drugs. \u00a0Mr. Lakshmikumaran will discuss recent global trends in compulsory licensing, examine the Indian legal framework, and discuss the lessons of the\u00a0Nexavar\u00a0<\/i>dispute.\u00a0 He will also explore the compatibility of India\u2019s compulsory licensing regime with the WTO\u2019s TRIPS Agreement.<\/p>\n

LIDS will be co-hosting this event.<\/p>\n","protected":false},"excerpt":{"rendered":"

Event Date:\u00a0\u00a0Monday, Sept. 16, 2013\u00a0 Event Time:\u00a0\u00a012:00-1:00 p.m. Event Location:\u00a0 Wasserstein Hall Room B015,\u00a0 Harvard Law School Description: Mr. V. […]<\/p>\n","protected":false},"author":694,"featured_media":1942,"template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_tribe_events_status":"","_tribe_events_status_reason":"","footnotes":""},"tags":[63,47,62],"tribe_events_cat":[],"class_list":["post-1950","tribe_events","type-tribe_events","status-publish","has-post-thumbnail","hentry","tag-india","tag-public-health","tag-wto"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/tribe_events\/1950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/tribe_events"}],"about":[{"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/types\/tribe_events"}],"author":[{"embeddable":true,"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/users\/694"}],"version-history":[{"count":0,"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/tribe_events\/1950\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/media\/1942"}],"wp:attachment":[{"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/media?parent=1950"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/tags?post=1950"},{"taxonomy":"tribe_events_cat","embeddable":true,"href":"https:\/\/orgs.law.harvard.edu\/lids\/wp-json\/wp\/v2\/tribe_events_cat?post=1950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}